CSL Limited
CSL.AXASXLog in to unlock analysis summary free on one stock of your choice.
Log in to unlock detailed analysis free on one stock of your choice.
| USD, millions | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 15,430 | 14,690 | 13,174 | 10,493 |
| Gross Profit | 7,951 | 7,561 | 6,708 | 5,664 |
| Operating Income | 2,959 | 2,764 | 2,102 | 2,316 |
| Net Income | 3,002 | 2,642 | 2,194 | 2,255 |
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.